661 related articles for article (PubMed ID: 25899785)
21. Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.
Lee VH; Tin VP; Choy TS; Lam KO; Choi CW; Chung LP; Tsang JW; Ho PP; Leung DK; Ma ES; Liu J; Shek TW; Kwong DL; Leung TW; Wong MP
J Thorac Oncol; 2013 Sep; 8(9):1148-55. PubMed ID: 23945384
[TBL] [Abstract][Full Text] [Related]
22. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.
Ellis PM; Shepherd FA; Millward M; Perrone F; Seymour L; Liu G; Sun S; Cho BC; Morabito A; Leighl NB; Stockler MR; Lee CW; Wierzbicki R; Cohen V; Blais N; Sangha RS; Favaretto AG; Kang JH; Tsao MS; Wilson CF; Goldberg Z; Ding K; Goss GD; Bradbury PA; ; ;
Lancet Oncol; 2014 Nov; 15(12):1379-88. PubMed ID: 25439692
[TBL] [Abstract][Full Text] [Related]
23. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.
Oxnard GR; Lo PC; Nishino M; Dahlberg SE; Lindeman NI; Butaney M; Jackman DM; Johnson BE; Jänne PA
J Thorac Oncol; 2013 Feb; 8(2):179-84. PubMed ID: 23328547
[TBL] [Abstract][Full Text] [Related]
24. Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.
Zhu L; Lopez S; Bellone S; Black J; Cocco E; Zigras T; Predolini F; Bonazzoli E; Bussi B; Stuhmer Z; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
Tumour Biol; 2015 Jul; 36(7):5505-13. PubMed ID: 25669172
[TBL] [Abstract][Full Text] [Related]
25. Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer.
Nagano T; Tachihara M; Nishimura Y
Drugs Today (Barc); 2019 Apr; 55(4):231-236. PubMed ID: 31050691
[TBL] [Abstract][Full Text] [Related]
26. A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report.
Zhou T; Xiong Q; Hong C; Wang Q; Wang W; Xu C; Cai J;
Medicine (Baltimore); 2022 Aug; 101(34):e30269. PubMed ID: 36042660
[TBL] [Abstract][Full Text] [Related]
27. Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial.
Song Z; Lv D; Chen SQ; Huang J; Li Y; Ying S; Wu X; Hua F; Wang W; Xu C; Bei T; Gao C; Sun Z; Zhang Y; Lu S
Clin Cancer Res; 2022 Feb; 28(3):461-467. PubMed ID: 34753778
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of dacomitinib in patients with HER2-positive gastric cancer.
Oh DY; Lee KW; Cho JY; Kang WK; Im SA; Kim JW; Bang YJ
Gastric Cancer; 2016 Oct; 19(4):1095-1103. PubMed ID: 26581547
[TBL] [Abstract][Full Text] [Related]
29. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives.
Lavacchi D; Mazzoni F; Giaccone G
Drug Des Devel Ther; 2019; 13():3187-3198. PubMed ID: 31564835
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
Sepúlveda-Sánchez JM; Vaz MÁ; Balañá C; Gil-Gil M; Reynés G; Gallego Ó; Martínez-García M; Vicente E; Quindós M; Luque R; Ramos A; Ruano Y; Pérez-Segura P; Benavides M; Sánchez-Gómez P; Hernández-Laín A
Neuro Oncol; 2017 Oct; 19(11):1522-1531. PubMed ID: 28575464
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).
Cheng Y; Mok TS; Zhou X; Lu S; Zhou Q; Zhou J; Du Y; Yu P; Liu X; Hu C; Lu Y; Zhang Y; Lee KH; Nakagawa K; Linke R; Wong CH; Tang Y; Zhu F; Wilner KD; Wu YL
Lung Cancer; 2021 Apr; 154():176-185. PubMed ID: 33721611
[TBL] [Abstract][Full Text] [Related]
32. Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions.
Piotrowska Z; Costa DB; Oxnard GR; Huberman M; Gainor JF; Lennes IT; Muzikansky A; Shaw AT; Azzoli CG; Heist RS; Sequist LV
Ann Oncol; 2018 Oct; 29(10):2092-2097. PubMed ID: 30351341
[TBL] [Abstract][Full Text] [Related]
33. Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.
Kosaka T; Tanizaki J; Paranal RM; Endoh H; Lydon C; Capelletti M; Repellin CE; Choi J; Ogino A; Calles A; Ercan D; Redig AJ; Bahcall M; Oxnard GR; Eck MJ; Jänne PA
Cancer Res; 2017 May; 77(10):2712-2721. PubMed ID: 28363995
[TBL] [Abstract][Full Text] [Related]
34. Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report.
Peng W; Pu X; Jiang M; Wang J; Li J; Li K; Xu Y; Xu F; Chen B; Wang Q; Cao J; Chen Y; Wu L
Lung Cancer; 2021 Feb; 152():66-70. PubMed ID: 33352385
[TBL] [Abstract][Full Text] [Related]
35. p95HER2 truncated form in resected non-small cell lung cancer.
Cappuzzo F; Cho YG; Sacconi A; Alì G; Siclari O; Incarbone M; Destro A; Terracciano L; Fontanini G; Marchetti A; Roncalli M; Varella-Garcia M
J Thorac Oncol; 2012 Mar; 7(3):520-7. PubMed ID: 22307009
[TBL] [Abstract][Full Text] [Related]
36. Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas.
Gow CH; Chang HT; Lim CK; Liu CY; Chen JS; Shih JY
Genes Chromosomes Cancer; 2017 May; 56(5):373-381. PubMed ID: 28063177
[TBL] [Abstract][Full Text] [Related]
37. Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea.
Lee K; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Cancer Res Treat; 2020 Jan; 52(1):292-300. PubMed ID: 31345011
[TBL] [Abstract][Full Text] [Related]
38. Poziotinib for Patients With
Elamin YY; Robichaux JP; Carter BW; Altan M; Gibbons DL; Fossella FV; Lam VK; Patel AB; Negrao MV; Le X; Mott FE; Zhang J; Feng L; Blumenschein G; Tsao AS; Heymach JV
J Clin Oncol; 2022 Mar; 40(7):702-709. PubMed ID: 34550757
[TBL] [Abstract][Full Text] [Related]
39. Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study).
Zhang B; Shi C; Gao Z; Zhong H; Xiong L; Gu A; Wang W; Chu T; Zhang W; Wang H; Zhang X; Zhong R; Han B
BMC Cancer; 2022 Mar; 22(1):294. PubMed ID: 35305596
[TBL] [Abstract][Full Text] [Related]
40. Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer.
Mok T; Lee K; Tang M; Leung L
Future Oncol; 2014 Apr; 10(5):813-22. PubMed ID: 24799062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
